Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Crinetics Pharmaceuticals (CRNX) Equity Ratio (2017 - 2025)

Crinetics Pharmaceuticals has reported Equity Ratio over the past 9 years, most recently at 0.88 for Q4 2025.

  • For Q4 2025, Equity Ratio fell 4.61% year-over-year to 0.88; the TTM value through Dec 2025 reached 0.88, down 4.61%, while the annual FY2025 figure was 0.88, 4.61% down from the prior year.
  • Equity Ratio for Q4 2025 was 0.88 at Crinetics Pharmaceuticals, down from 0.9 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.95 in Q4 2021 and troughed at 0.85 in Q4 2023.
  • A 5-year average of 0.9 and a median of 0.9 in 2022 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: decreased 6.48% in 2023 and later increased 8.83% in 2024.
  • Year by year, Equity Ratio stood at 0.95 in 2021, then dropped by 5.02% to 0.9 in 2022, then fell by 5.53% to 0.85 in 2023, then rose by 8.83% to 0.92 in 2024, then fell by 4.61% to 0.88 in 2025.
  • Business Quant data shows Equity Ratio for CRNX at 0.88 in Q4 2025, 0.9 in Q3 2025, and 0.91 in Q2 2025.